Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
Torin 1 Chemical Structure
|Product name: Torin 1|
|Cat. No.: HY-13003|
Torin 1 is potent and selective mTOR inhibitor (IC50 = 2 - 10 nM for mTORC1 and mTORC2). Torin1 displays 200-fold selectivity for mTOR over DNA-PK, ATM and hVps34.
|M.Wt||607.64||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
DMSO: ＜ 6.4 mg/mL; DMSO: ≥ 6 mg/mL (Need ultrasonic or warming)
|1 mg||5 mg||10 mg|
|1 mM||1.6457 mL||8.2286 mL||16.4571 mL|
|5 mM||0.3291 mL||1.6457 mL||3.2914 mL|
|10 mM||0.1646 mL||0.8229 mL||1.6457 mL|
1 . Timothy R. Peterson, Shomit S. Sengupta, Thurl E. Harris, Anne E. Carmack, Seong A. Kang, Eric Balderas, David A. Guertin, Katherine L. Madden, Anne E. Carpenter, Brian N. Finck, David M. Sabatini.mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway.Cell, Volume 146, Issue 3, 408-420, 5 August 2011.
The nutrient- and growth factor-responsive kinase mTOR complex 1 (mTORC1) regulates many processes that control growth, including protein synthesis, autophagy, and lipogenesis. Through unknown mechanisms, mTORC1 promotes the function of SREBP, a master regulator of lipo- and sterolgenic gene transcription. Here, we demonstrate that mTORC1 regulates SREBP by controlling the nuclear entry of lipin 1, a phosphatidic acid phosphatase. Dephosphorylated, nuclear, catalytically active lipin 1 promotes nuclear remodeling and mediates the effects of mTORC1 on SREBP target gene, SREBP promoter activity, and nuclear SREBP protein abundance. Inhibition of mTORC1 in the liver significantly impairs SREBP function and makes mice resistant, in a lipin 1-dependent fashion, to the hepatic steatosis and hypercholesterolemia induced by a high-fat and -cholesterol diet. These findings establish lipin 1 as a key component of the mTORC1-SREBP pathway.
AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM with excellent selectivity (～1,000-fold) against PI3K isoforms and ATM/DNA-PK.
AZD2014 is a novel mTOR inhibitor with IC50 of 2.8 nM; highly selective against multiple PI3K isoforms ((alpha)/(beta)/(gamma)/(delta)).
CC-223 is a potent mTOR kinase inhibitor (IC50=16 nM), with >150-fold sensitivity over the related lipid kinase PI3K(alpha) (IC50=4 (mu)M).
Deforolimus(AP23573; MK-8669; Ridaforolimus) is a selective mTOR inhibitor with IC50 of 0.2 nM; while not classified as a prodrug, mTOR inhibition and FKBP12 binding is similar to rapamycin.
ETP-46464 is a cell-permeable quinoline-containing heterotricyclic compound that acts as a potent inhibitor against mTOR, ATR, DNA-PK, PI 3-K(alpha), and ATM (IC50= 0.6, 14, 36, 170, and 545 nM, respectively).
Everolimus (RAD001) is a mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM.
GDC-0084 is a potent, selective inhibitor of Class I PI3K and mTOR with good penetration across the blood-brain barrier.
GDC-0349 is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 3.8 nM; >700-fold selectivity over PI3K(alpha) and other 266 kinases.
GDC-0980 (RG7422) is a potent, class I PI3K inhibitor for PI3K(alpha)/(beta)/(delta)/(gamma) with IC50 of 5 nM/27 nM/7 nM/14 nM, respectively; also a mTOR inhibitor with Ki of 17 nM, and highly selective versus others PIKK family kinases.
GNE-317 is a potent PI3K/mTOR inhibitor that can cross the blood–brain barrier; shows potent suppression of the PI3K pathway in the brain of mice with intact BBB.